Now showing items 1-9 of 9

    • Androgen receptor functions in prostate cancer development and progression 

      Balk, Steven P (Medknow Publications & Media Pvt Ltd, 2014)
      The androgen receptor (AR) is critical for the normal development of prostate and for its differentiated functions. The consistent expression of AR in prostate cancer (PCa), and its continued activity in PCa that relapse ...
    • AR, the Cell Cycle, and Prostate Cancer 

      Balk, Steven Paul; Knudsen, Karen E. (The Nuclear Receptor Signaling Atlas, 2008)
      The androgen receptor (AR) is a critical effector of prostate cancer development and progression. The dependence of this tumor type on AR activity is exploited in treatment of disseminated prostate cancers, wherein ablation ...
    • Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide 

      Nowak, Michael; Arredouani, Mohammed S.; Tun-Kyi, Adrian; Schmidt-Wolf, Ingo; Sanda, Martin George; Balk, Steven Paul; Exley, Mark Adrian (Public Library of Science, 2010)
      Numerical and functional defects of invariant natural killer T cells (iNKT) have been documented in human and mouse cancers, resulting in a defect in IFN production in several malignancies. iNKT cells recognize glycolipids ...
    • Doxycycline Regulated Induction of AKT in Murine Prostate Drives Proliferation Independently of p27 Cyclin Dependent Kinase Inhibitor Downregulation 

      Wang, Hongyun; Xu, Youyuan; Fang, Zi; Chen, Sen; Balk, Steven Paul; Yuan, Xin (Public Library of Science, 2012)
      The PI3 kinase/AKT pathway has been shown to increase degradation of the p27 cyclin dependent kinase inhibitor through phosphorylation of consensus AKT sites on p27 and SKP2, and AKT driven proliferation may be checked by ...
    • Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation 

      Hsieh, Chen-Lin; Fei, Teng; Chen, Yiwen; Li, Tiantian; Gao, Yanfei; Wang, Xiaodong; Sun, Tong; Sweeney, Christopher J; Lee, Gwo-Shu Mary; Chen, Shaoyong; Balk, Steven Paul; Liu, Xiaole (Shirley) Shirley; Brown, Myles Avery; Kantoff, Philip Wayne (Proceedings of the National Academy of Sciences, 2014)
      The androgen receptor (AR) is a key factor that regulates the behavior and fate of prostate cancer cells. The AR-regulated network is activated when AR binds enhancer elements and modulates specific enhancer–promoter ...
    • Loss of Wave1 gene defines a subtype of lethal prostate cancer 

      Sowalsky, Adam G.; Sager, Rebecca; Schaefer, Rachel J.; Bratslavsky, Gennady; Pandolfi, Pier Paolo; Balk, Steven P.; Kotula, Leszek (Impact Journals LLC, 2015)
      Genetic alterations involving TMPRSS2-ERG alterations and deletion of key tumor suppressor genes are associated with development and progression of prostate cancer (PCa). However, less defined are early events that may ...
    • Polycomb-independent activity of EZH2 in castration resistant prostate cancer 

      Xu, Kexin; Wu, Zhenhua; Groner, Anna Claire; He, Housheng H; Cai, Changmeng; Stack, Edward C; Loda, Massimo; Liu, Tao; Morrissey, Colm; Vessella, Robert L; Kantoff, Philip Wayne; Balk, Steven Paul; Liu, Xiaole Shirley; Brown, Myles Avery (BioMed Central, 2013)
    • Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation 

      Liu, Xiaming; Han, Weiwei; Gulla, Sarah; Simon, Nicholas I.; Gao, Yanfei; Cai, Changmeng; Yang, Hongmei; Zhang, Xiaoping; Liu, Jihong; Balk, Steven P.; Chen, Shaoyong (Impact Journals LLC, 2016)
      The phosphoprotein phosphatases are emerging as important androgen receptor (AR) regulators in prostate cancer (PCa). We reported previously that the protein phosphatase 1 catalytic subunit (PP1α) can enhance AR activity ...
    • Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy 

      Li, Zhenfei; Alyamani, Mohammad; Li, Jianneng; Rogacki, Kevin; Abazeed, Mohamed; Upadhyay, Sunil K.; Balk, Steven P.; Taplin, Mary-Ellen; Auchus, Richard J.; Sharifi, Nima (2016)
      Abiraterone blocks androgen synthesis and prolongs survival in castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis1,2. Abiraterone is metabolized in patients to D4A, which has ...